487 related articles for article (PubMed ID: 26529477)
21. Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine.
Narayana N; Cox S; Shaltiel S; Taylor SS; Xuong N
Biochemistry; 1997 Apr; 36(15):4438-48. PubMed ID: 9109651
[TBL] [Abstract][Full Text] [Related]
22. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
Roskoski R
Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
[TBL] [Abstract][Full Text] [Related]
23. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
Zhu Y; Hu X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
[TBL] [Abstract][Full Text] [Related]
24. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2023 May; 191():106774. PubMed ID: 37075870
[TBL] [Abstract][Full Text] [Related]
25. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
Modi SJ; Kulkarni VM
J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
[TBL] [Abstract][Full Text] [Related]
26. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract][Full Text] [Related]
27. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
28. Rational design of inhibitors that bind to inactive kinase conformations.
Liu Y; Gray NS
Nat Chem Biol; 2006 Jul; 2(7):358-64. PubMed ID: 16783341
[TBL] [Abstract][Full Text] [Related]
29. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
Badrinarayan P; Sastry GN
J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
[TBL] [Abstract][Full Text] [Related]
30. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
31. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski R
Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
[TBL] [Abstract][Full Text] [Related]
32. Non-ATP competitive protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2010; 17(25):2804-21. PubMed ID: 20586715
[TBL] [Abstract][Full Text] [Related]
33. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
Ung PM; Schlessinger A
ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
[TBL] [Abstract][Full Text] [Related]
34. From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ.
Bethke E; Pinchuk B; Renn C; Witt L; Schlosser J; Peifer C
ChemMedChem; 2016 Dec; 11(24):2664-2674. PubMed ID: 27885822
[TBL] [Abstract][Full Text] [Related]
35. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
36. Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors.
Zhu Y; Alqahtani S; Hu X
Molecules; 2021 Mar; 26(6):. PubMed ID: 33810025
[TBL] [Abstract][Full Text] [Related]
37. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
[TBL] [Abstract][Full Text] [Related]
38. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
[TBL] [Abstract][Full Text] [Related]
39. Kinase hinge binding scaffolds and their hydrogen bond patterns.
Xing L; Klug-Mcleod J; Rai B; Lunney EA
Bioorg Med Chem; 2015 Oct; 23(19):6520-7. PubMed ID: 26358279
[TBL] [Abstract][Full Text] [Related]
40. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
